Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Larson

Showing results (211-220 of 383) with videos related to

Pageof 39
Sort By:
Ejhaem|June 16, 2025
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax TherapyRafael Madero-Marroquin, Joseph Cannova, Emily Dworkin, et al.
Haematologica|February 18, 2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice dailyTimothy P Hughes, Andreas Hochhaus, Hagop M Kantarjian, et al.
Cancer Chemotherapy and Pharmacology|August 29, 2014
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103)Jan H Beumer, Kouros Owzar, Lionel D Lewis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 26, 2016
Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity ConditioningStephanie B Tsai, Hongtao Liu, Tsiporah Shore, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 7, 2007
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemiaShuangli Mi, Jun Lu, Miao Sun, et al.
Blood|March 15, 2003
Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemiaM William Lensch, Marc Tischkowitz, Tracy A Christianson, et al.
Leukemia & Lymphoma|October 29, 2013
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotypeXavier Poiré, Barry K Moser, Robert E Gallagher, et al.
Blood|March 8, 2007
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B studySusan P Whitman, Amy S Ruppert, Guido Marcucci, et al.
Blood|October 18, 2007
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplicationsSusan P Whitman, Amy S Ruppert, Michael D Radmacher, et al.
Blood|October 7, 2011
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissionsHongtao Liu, Elizabeth S Rich, Lucy Godley, et al.
Pageof 39

Showing results (211-220 of 383) with videos related to

Sort By:
Pageof 39
Ejhaem|June 16, 2025
Outcomes for Patients With Myeloid Neoplasms Treated With Chemotherapy Plus Venetoclax After Prior Venetoclax TherapyRafael Madero-Marroquin, Joseph Cannova, Emily Dworkin, et al.
Haematologica|February 18, 2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice dailyTimothy P Hughes, Andreas Hochhaus, Hagop M Kantarjian, et al.
Cancer Chemotherapy and Pharmacology|August 29, 2014
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103)Jan H Beumer, Kouros Owzar, Lionel D Lewis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 26, 2016
Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity ConditioningStephanie B Tsai, Hongtao Liu, Tsiporah Shore, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 7, 2007
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemiaShuangli Mi, Jun Lu, Miao Sun, et al.
Blood|March 15, 2003
Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemiaM William Lensch, Marc Tischkowitz, Tracy A Christianson, et al.
Leukemia & Lymphoma|October 29, 2013
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotypeXavier Poiré, Barry K Moser, Robert E Gallagher, et al.
Blood|March 8, 2007
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B studySusan P Whitman, Amy S Ruppert, Guido Marcucci, et al.
Blood|October 18, 2007
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplicationsSusan P Whitman, Amy S Ruppert, Michael D Radmacher, et al.
Blood|October 7, 2011
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissionsHongtao Liu, Elizabeth S Rich, Lucy Godley, et al.
Pageof 39